跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
洪 榮志
教授
醫學系外科學科
電話
02-28757027 ext. 304, 02-28757027 ext. 269
電子郵件
cjhong007
gmail
com
h-index
h10-index
h5-index
1758
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
423
引文
12
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
97
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2024
每年研究成果
概覽
指紋
網路
研究成果
(58)
類似的個人檔案
(6)
指紋
查看啟用 Jung-Jyh Hung 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Active Tuberculosis
15%
Advanced Lung Adenocarcinoma
21%
Aiolos
15%
American Thoracic Society
15%
Completely Resected
78%
Distant Metastasis
27%
Epithelial-mesenchymal Transition
22%
European Respiratory Society
15%
Factors Predicting
18%
General Hospital
23%
Ground-glass Opacity
16%
Hazard Ratio
16%
High Risk
15%
Hypoxia-inducible factor-1α (HIF-1α)
23%
International Association for the Study of Lung Cancer (IASLC)
15%
Local Recurrence
19%
Lung Adenocarcinoma
76%
Lung Cancer
15%
Lung Cancer Cells
16%
Lymph Node Metastasis
15%
Micropapillary
31%
Multivariate Analysis
28%
Node-negative
16%
Non-small Cell Lung Cancer (NSCLC)
51%
Overall Survival
69%
Overall Survival Rate
14%
Overexpression
34%
Pathological Stage
20%
PD-L1 Expression
14%
Post-recurrence Survival
41%
Probability of Freedom
27%
Prognostic Factors
80%
Prognostic Significance
32%
Prognostic Value
19%
Programmed Death-ligand 1 (PD-L1)
15%
Resectable Lung Cancer
15%
Resection
15%
Significant Predictors
17%
Solid Predominant
26%
Stage I Lung Cancer
37%
Stage IB
19%
Stem Cells
17%
Surgical Outcomes
19%
Surgical Resection
21%
Taipei
25%
Taiwan
20%
Tumor
21%
Tumor Size
26%
Twist1
23%
Visceral Pleural Invasion
25%
Medicine and Dentistry
Adenocarcinoma
13%
Adjuvant Chemotherapy
12%
Cancer Cell
22%
Cancer Stem Cell
15%
Carcinosarcoma
7%
Computer Assisted Tomography
8%
COVID-19
7%
Disease Free Survival
11%
Diseases
13%
Distant Metastasis
25%
Endothelial Cell
7%
Epidermal Growth Factor Receptor
7%
Esophageal Squamous Cell Carcinoma
8%
Esophagectomy
12%
Ground Glass Opacity
16%
Hazard Ratio
13%
Hepatocellular Carcinoma
8%
Kruppel Like Factor 4
7%
Liver Metastasis
10%
Lung Adenocarcinoma
84%
Lung Cancer
69%
Lung Nodule
15%
Lymph Node Metastasis
26%
Mesenchymal-Epithelial Transition
19%
Metastatic Carcinoma
40%
Micropapillary
28%
Multivariate Analysis
22%
Neoplasm
60%
Non Small Cell Lung Cancer
71%
Operating Room
9%
Overall Survival
65%
Pneumonectomy
43%
Prognostic Factor
73%
Protein Kinases
7%
Radiation Therapy
10%
Recurrent Disease
100%
Retroperitoneal Lymph Node Dissection
10%
Scoring System
7%
Squamous Cell Carcinoma
16%
Subclavian Artery
7%
Surgery
46%
Survival Analysis
9%
Survival Rate
20%
Thoracic Wall
7%
Thoracotomy
7%
Tracheoesophageal Fistula
7%
Tracheostomy
7%
Tumor Cell
7%
Tumor Recurrence
10%
Video-Assisted Thoracoscopic Surgery
15%
